Biotie Therapies Articles
Launch of Biotie/Lundbeck's Selincro will see a paradigm shift in alcohol addiction market
10 May 2013
Briefs: New research deals for AstraZeneca and Novo Nordisk; Lundbeck's Selincro launched in Europe
22 April 2013
ANN meeting highlights: Novartis' Gilenya, Lundbeck's Azilect, Orion's ODM-101, Biotie's tozadenant
21 March 2013
Biotie's Parkinson's drug tozadenant clears Phase IIb study
11 December 2012
Lundbeck takes 5% stake in Biotie; amends Selincro licensing deal
7 September 2012
Roche returns rights to Biotie Therapies SYN120
27 June 2012
UCB pulls out of Biotie partnership on SYN118
25 November 2011
Repligen to buy Novozymes Biopharma Sweden business for $23 upfront; Biotie pulls out of Newron acquisition
28 October 2011
Biotie to buy Newron for 45 million euros, creating a European leader in CNS drug development
27 September 2011
Biotie to acquire Synosia to create leading CNS development group in $121.5 million deal
11 January 2011
Showing 1-14 of 14 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
